Test of Variables of Attention

Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress

Retrieved on: 
수요일, 5월 31, 2023
Hardware, Health Technology, Technology, Pharmaceutical, Mental Health, Teens, Parenting, Clinical Trials, Electronic Games, Other Technology, Science, Software, Entertainment, Consumer, Research, Health, Test of Variables of Attention, Face, ADHD, Attention deficit hyperactivity disorder predominantly inattentive, ASCP, Variable, Patient, ACS, Annual general meeting, FDA, Society, Safety, Dietary supplement, Yolo Akili

The poster presentations highlight results of Akili’s STARS-ADHD-Adolescents label expansion trial evaluating the efficacy and safety of EndeavorRx in adolescents ages 13-17 with ADHD.

Key Points: 
  • The poster presentations highlight results of Akili’s STARS-ADHD-Adolescents label expansion trial evaluating the efficacy and safety of EndeavorRx in adolescents ages 13-17 with ADHD.
  • After four weeks of treatment with EndeavorRx, trial participants saw significant improvements across a wide range of clinical outcomes, including in their attention and ADHD-related symptoms.
  • “The data being presented expand the evidence supporting the safety and efficacy of EndeavorRx to improve attention and functioning in adolescents with ADHD,” said Scott Kollins, Ph.D., chief medical officer of Akili.
  • “Teenagers have been significantly impacted by our current mental health crisis, yet face substantial challenges in accessing effective treatment for ADHD.

PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

Retrieved on: 
목요일, 5월 4, 2023
Research, Mental Health, Electronic Games, Entertainment, Clinical Trials, Biotechnology, Alternative Medicine, Pharmaceutical, Health, Science, LSE, Clinical trial, ADHD, Quality of life, PureTech Health, Attention deficit hyperactivity disorder predominantly inattentive, ACS, Patient, Yolo Akili, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PRTC, Test of Variables of Attention, Food, Safety, Dietary supplement

STARS-ADHD-Adult was designed as a pivotal clinical trial to enable registration with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • STARS-ADHD-Adult was designed as a pivotal clinical trial to enable registration with the U.S. Food and Drug Administration (FDA).
  • The trial demonstrated statistically significant improvement in attention functioning after six weeks of treatment, achieving its predefined primary efficacy outcome.
  • Significant improvements were also seen across a range of secondary and exploratory outcomes, including clinical assessments of ADHD-related symptoms and a validated measure of quality of life.
  • The multi-center open-label study (NCT05183919) enrolled 221 adults, 18 years of age and older, with inattentive or combined-type ADHD.

Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

Retrieved on: 
수요일, 5월 3, 2023
Mental Health, Health, Technology, Telemedicine, Virtual Medicine, Health Technology, Software, Clinical Trials, Face, Clinical trial, ADHD, Quality of life, Multimedia, Attention, Attention deficit hyperactivity disorder predominantly inattentive, Patient, ACS, Adolescence, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Test of Variables of Attention, Food, Safety, Dietary supplement, Yolo Akili

STARS-ADHD-Adult was designed as a pivotal clinical trial to enable registration with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • STARS-ADHD-Adult was designed as a pivotal clinical trial to enable registration with the U.S. Food and Drug Administration (FDA).
  • The trial demonstrated statistically significant improvement in attention functioning after six weeks of treatment, achieving its predefined primary efficacy outcome.
  • Significant improvements were also seen across a range of secondary and exploratory outcomes, including clinical assessments of ADHD-related symptoms and a validated measure of quality of life.
  • For both objective measures of attention and clinical outcomes, the improvements observed in adults surpassed those in both the pediatric and adolescent patient populations.

Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes

Retrieved on: 
목요일, 1월 5, 2023
Mental Health, Health, Other Health, Managed Care, Clinical Trials, Biotechnology, Patient, Test of Variables of Attention, Multimedia, ADHD, ACS, Safety, FDA, Attention deficit hyperactivity disorder predominantly inattentive, Pharmaceutical industry, Yolo Akili

The pivotal study achieved its predefined primary efficacy outcome, showing statistically significant improvement in attentional functioning after four weeks of treatment.

Key Points: 
  • The pivotal study achieved its predefined primary efficacy outcome, showing statistically significant improvement in attentional functioning after four weeks of treatment.
  • Consistent improvements were also seen in a range of secondary measures of ADHD-related inattention symptoms and functioning.
  • The multi-center open-label study enrolled 162 adolescents ages 13-17 with inattentive or combined-type ADHD.
  • TOVA is a computerized test cleared by FDA to assess attention deficits and evaluate the effects of interventions in ADHD.

PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

Retrieved on: 
목요일, 5월 26, 2022
Technology, FDA, Other Technology, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Data Management, Work, Cancer, Risk, Optimism, Company, Nausea, PureTech Health, Dizziness, Medicine, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Variable, Degenerative disease, Environment, Patient, Biology, LSE, RBLX, COVID-19, Aggression, Government budget balance, FDA, Research, Brain, Industry, U.S. FDA, Frustration, Creativity, Partnership, ADHD, Forward-looking statement, Communication, Test of Variables of Attention, Imagination, BIG, Therapy, Headache, Twitter, Emotion, 3D, SEC, Entrepreneurship, Axis, NYSE, PRTC, Attention deficit hyperactivity disorder predominantly inattentive, Annual report, CEO, Pharmaceutical industry, Yolo Akili, Roblox

Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.

Key Points: 
  • Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.
  • Akili has captured our imagination with its prescription treatment for children with ADHD delivered through an action video game experience and shares our vision and enthusiasm for whats possible through interactive, digital experiences.
  • Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.
  • Initially, the companies will establish an exclusive Roblox rewards exchange tied to Akilis EndeavorRx treatment (see full indication below).

Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

Retrieved on: 
목요일, 5월 26, 2022
Software, Managed Care, Entertainment, General Health, Data Management, Mental Health, Medical Devices, Technology, General Entertainment, Nursing, Practice Management, Health, Work, Risk, Optimism, Nausea, Dizziness, Medicine, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Variable, Patient, RBLX, COVID-19, Aggression, Government budget balance, FDA, Research, Brain, Industry, Frustration, Creativity, Partnership, ADHD, Forward-looking statement, Communication, Test of Variables of Attention, Imagination, Headache, Emotion, 3D, Entrepreneurship, NYSE, Attention deficit hyperactivity disorder predominantly inattentive, CEO, Pharmaceutical industry, Yolo Akili, Roblox

Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.

Key Points: 
  • Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients lives.
  • Initially, the companies will establish an exclusive Roblox rewards exchange tied to Akilis EndeavorRx treatment (see full indication below).
  • Our FDA-cleared video game treatment demonstrates that medicine can be enjoyable, and that is only the beginning.
  • Akili has challenged traditional perceptions of medicine and created EndeavorRx , the first and only prescription video game treatment for children with ADHD, cleared by the U.S. Food and Drug Administration (FDA).